
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Upcoming Result Date: Jan 20, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q2 FY22
Gian Lifecare Ltd (GIANLIFE) is currently trading at 10.01 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gian Life Care Limited is primarily engaged in providing diagnostic and healthcare tests, operating major labs in Kanpur and Lucknow. Established in 1995, Gian Pathology has evolved into a large diagnostic center under the leadership of Arun Kumar Gupta. The company offers a wide range of approximately 1,344 diagnostic tests in multiple disciplines including molecular biology. Gian Life Care expanded through an IPO, issuing over 1.4 million equity shares, raising Rs 3.11 Crore. Plans are underway to set up more diagnostic labs across various regions, indicating growth ambitions.
Over the past 52 weeks, Gian Lifecare Ltd has traded between a low of ₹7.08 and a high of ₹20.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gian Lifecare Ltd has a market capitalization of approximately 10.85. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gian Lifecare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the Healthcare sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
You can buy shares of Gian Lifecare Ltd (GIANLIFE) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.
Based on its market capitalization of 10.85 Cr, Gian Lifecare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gian Lifecare Ltd operates in the Healthcare sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gian Lifecare Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Gian Lifecare Ltd currently does not pay dividends. Companies that do not pay dividends often reinvest profits to support business growth or strengthen operations.
Key risks associated with Gian Lifecare Ltd include sector-specific challenges in the Healthcare industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.
Bearish
5
Neutral
5
Bullish
4
Bearish
22
Neutral
5
Bullish
19
Bearish
17
Neutral
0
Bullish
15
Market Cap
₹ 11 Cr
P/E
—
Healthcare
Diagnostic Services
11 Cr
Low Risk
—
47.6
—
0.6
20.50
7.08
Sales CAGR
1Y
-49.47%
3Y
-25.33%
5Y
-2.81%
10Y
—
Profit CAGR
1Y
-100.96%
3Y
-67.13%
5Y
-32.72%
10Y
—
ROE
TTM
-0.19%
3Y
10.44%
5Y
15.44%
10Y
—
ROCE
TTM
2.13%
3Y
14.60%
5Y
20.56%
10Y
—
Performance
UNDER PERFORMER
Valuation
REASONABLE
Growth
SLUGGISH
Profitability
LOW MARGIN
Technicals
Bearish
Risk
MODERATE RISK